SCHEMBL13828583

SCHEMBL13828583

Cc1c(Cl)nc(Cl)nc1N1CCOCC1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.48
PDE10A Q9Y233 3/20 0.45
PDE4A P27815 1/20 0.41
PDE4B Q07343 1/20 0.41
PDE4C Q08493 1/20 0.41
PDE4D Q08499 1/20 0.41
POLB P06746 2/20 0.41
NUDT1 P36639 1/20 0.40
MAPT P10636 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
KMT2A Q03164 4/20 0.39
NPSR1 Q6W5P4 1/20 0.39
ALDH1A1 P00352 3/20 0.39
HPGD P15428 1/20 0.39
KHK P50053 1/20 0.39
MEN1 O00255 1/20 0.38
GAA P10253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16117369 0.86 SMN1; SMN2 (0.48) SMN1; SMN2PDE4APDE4BPDE4CPDE4D
SCHEMBL16036853 0.84 PIK3R1 (0.48) SMN1; SMN2PDE10AMAPTKMT2ANPSR1
SCHEMBL4973147 0.83 SMN1; SMN2 (0.48) SMN1; SMN2POLBMAPTL3MBTL1KMT2A
SCHEMBL10621985 0.83 NUDT1 (0.55) PDE10APDE4APDE4BPDE4CPDE4D
SCHEMBL23773549 0.80 SMN1; SMN2 (0.46) SMN1; SMN2PDE10APDE4APDE4BPDE4C
SCHEMBL13828994 0.80 NUDT1 (0.46) SMN1; SMN2PDE4APDE4BPDE4CPDE4D
SCHEMBL13828560 0.80 SMN1; SMN2 (0.53) SMN1; SMN2PDE10APDE4APDE4BPDE4C
SCHEMBL26795912 0.80 PDE4A (0.42) SMN1; SMN2PDE10APDE4APDE4BPDE4C
SCHEMBL13828670 0.79 SMN1; SMN2 (0.46) SMN1; SMN2PDE4APDE4BPDE4CPDE4D
SCHEMBL26975122 0.79 CTSK (0.57) SMN1; SMN2POLBKMT2AALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11858915-B2 Polo like kinase 4 inhibitors ORIC PHARMACEUTICALS, INC. (US) 2024-01-02 US disclosed
US-20230135152-A1 PIKFYVE KINASE INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-05-04 US disclosed
US-20230135152-A1 PIKFYVE KINASE INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-05-04 US disclosed
WO-2021163727-A1 PIKFYVE KINASE INHIBITORS AcuraStem Incorporated (US) 2021-08-19 WO disclosed
US-9801888-B2 Pyrimidine compounds as mTOR and PI3K inhibitors DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) 2017-10-31 US disclosed
US-20160136176-A1 NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) 2016-05-19 US disclosed
US-9315491-B2 Pyrimidine compounds as mTOR and PI3K inhibitors DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) 2016-04-19 US disclosed
US-9034311-B2 Pyridin-2(1 H)-one derivatives as JAK inhibitors ALMIRALL, S.A. (ES) 2015-05-19 US disclosed
US-20140271543-A1 PYRIDIN-2(1H)-ONE DERIVATIVES AS JAK INHIBITORS ALMIRALL, S.A. (ES) 2014-09-18 US disclosed
US-20140178360-A1 NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS DCB-USA LLC (US) 2014-06-26 US disclosed
EP-2739616-A1 PYRIDIN-2(1H)-ONE DERIVATIVES AS JAK INHIBITORS Almirall, S.A. (ES) 2014-06-11 EP disclosed
WO-2013017461-A1 PYRIDIN-2(1H)-ONE DERIVATIVES AS JAK INHIBITORS ALMIRALL, S.A. (ES) 2013-02-07 WO disclosed
US-20120288492-A1 NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS DCB-USA LLC (US) 2012-11-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230135152-A1 PIKFYVE KINASE INHIBITORS PIKFYVE, PIP5K1B, PIP5K1C SMN1; SMN2 2494/4885PDE10A 1421/4885PDE4A 657/4885
US-11858915-B2 Polo like kinase 4 inhibitors PLK4, PLK2, PLK3 SMN1; SMN2 2786/4885PDE10A 2023/4885PDE4A 661/4885
US-20120288492-A1 NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS MTOR, PIK3CA, TYMS SMN1; SMN2 3386/4885PDE10A 2180/4885PDE4A 1889/4885
US-20160136176-A1 NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS MTOR, PIK3CA, TYMS SMN1; SMN2 3386/4885PDE10A 2180/4885PDE4A 1889/4885
US-20140178360-A1 NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS MTOR, PIK3CA, TYMS SMN1; SMN2 3386/4885PDE10A 2180/4885PDE4A 1889/4885
US-20140271543-A1 PYRIDIN-2(1H)-ONE DERIVATIVES AS JAK INHIBITORS JAK1, JAK2, JAK3 SMN1; SMN2 3968/4885PDE10A 1875/4885PDE4A 2198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.